{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-008705","form_type":"8-K","ticker":"BKYI","cik":"0001019034","company_name":"BIO KEY INTERNATIONAL INC","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.522522+00:00","generated_at":"2026-06-17T07:32:00.691700+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BIO-key FY2022 revenue up 37% to $7.0M; net loss widens to $10.2M; Q1 2023 guidance strong","bullets":["FY2022 revenue $7.0M (+37% YoY); Q4 revenue $1.76M (+88% YoY), driven by Swivel Secure acquisition.","Net loss FY2022 $10.2M ($1.26 per share) vs $5.1M ($0.65 per share) in FY2021; included $1.8M goodwill impairment.","Gross margin improved to 70.9% from 67.3% due to higher software and services revenue mix.","Expects Q1 2023 revenue to significantly exceed strongest 2022 quarter; annual recurring revenue ~$7M.","Operating expenses rose to $14.7M (vs $8.4M); cost reduction initiatives underway to improve profitability."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-008705","json":"https://secwatch.observer/filing/0001437749-23-008705.json","markdown":"https://secwatch.observer/filing/0001437749-23-008705.md","text":"https://secwatch.observer/filing/0001437749-23-008705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1019034/000143774923008705/0001437749-23-008705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1019034/000143774923008705/bkyi20230330_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:32:00.691700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"410cddb16bfc9258bd5fc972a93f20eaf6de4cb8","claim":"BIO KEY INTERNATIONAL INC reported the year ended December 31, 2022 results: revenue $7.0M. Guidance initiated.","evidence_excerpt":"FY’22 revenue increased 37% to $7.0M from $5.1M in FY’21","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1019034/000143774923008705/0001437749-23-008705-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$7.0M"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"62df56a5e1284b39c0ebbb52b59e6c2023f64eb0","claim":"BIO KEY INTERNATIONAL INC reported the fourth quarter ended December 31, 2022 results: revenue $1.76M. Guidance initiated.","evidence_excerpt":"Q4’22 revenue increased 88% to $1.76M from $0.93M in Q4’21","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1019034/000143774923008705/0001437749-23-008705-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$1.76M"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}